Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response

Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the BCR-ABL1 tyrosine kinase. Although ABL1-specific tyrosine kinase inhibitors (TKIs) including nilotinib have dramatically improved the prognosis of patients with CML, the TKI efficacy depends on the individual patient. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Okamoto, Yuji, Hirano, Mitsuhito, Morino, Kai, Kajita, Masashi K., Nakaoka, Shinji, Tsuda, Mayuko, Sugimoto, Kei-ji, Tamaki, Shigehisa, Hisatake, Junichi, Yokoyama, Hisayuki, Igarashi, Tadahiko, Shinagawa, Atsushi, Sugawara, Takeaki, Hara, Satoru, Fujikawa, Kazuhisa, Shimizu, Seiichi, Yujiri, Toshiaki, Wakita, Hisashi, Nishiwaki, Kaichi, Tojo, Arinobu, Aihara, Kazuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561725/
https://www.ncbi.nlm.nih.gov/pubmed/36229495
http://dx.doi.org/10.1038/s41540-022-00248-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561725/
https://www.ncbi.nlm.nih.gov/pubmed/36229495
http://dx.doi.org/10.1038/s41540-022-00248-3

Ejemplares similares